Government-Owned Inventions; Availability for Licensing, 4498-4499 [2018-01928]
Download as PDF
<![CDATA[
4498
Federal Register / Vol. 83, No. 21 / Wednesday, January 31, 2018 / Notices
Dated: January 26, 2018.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–01929 Filed 1–30–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
sradovich on DSK3GMQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Chemo/Dietary Prevention Study
Section.
Date: February 22, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Drury Inn & Suites San Antonio
Riverwalk, 201 N St. Mary’s Street, San
Antonio, TX 78205.
Contact Person: Svetlana Kotliarova, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
Bethesda, MD 20892, 301–594–7945,
kotliars@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel.
Date: February 22–23, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Wardman Park Washington
DC Hotel, 2660 Woodley Road, NW,
Washington, DC 20008.
Contact Person: Alok Mulky, Ph.D.,
Scientific Review Officer, Center for
Scientific Review (CSR), National Institutes
of Health (NIH), 6701 Rockledge Dr, Room
4203, Bethesda, MD 20817, (301) 435–3566,
alok.mulky@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Mechanisms
of Cancer Therapeutics 2.
Date: February 26–27, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
18:47 Jan 30, 2018
Jkt 244001
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Careen K. Tang-Toth,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
MSC 7804, Bethesda, MD 20892, (301)435–
3504, tothct@csr.nih.gov.
Name of Committee: Musculoskeletal, Oral
and Skin Sciences Integrated Review Group;
Arthritis, Connective Tissue and Skin Study
Section.
Date: February 27–28, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Alexey Belkin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4102,
Bethesda, MD 20817, 301–435–1786,
alexey.belkin@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Learning, Memory, Language,
Communication and Related, Neurosciences.
Date: February 27, 2018.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Pier 2620 Hotel, 2620 Jones St, San
Francisco, CA 94133.
Contact Person: Susan Gillmor, Ph.D.,
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, Bethesda, MD 20892, 301–
435–1730, susan.gillmor@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 16–
245: Neural Regulation of Cancer.
Date: February 27, 2018.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ola Mae Zack Howard,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4192,
MSC 7806, Bethesda, MD 20892, 301–451–
4467, howardz@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Cell Biology, Developmental
Biology, and Bioengineering.
Date: February 27–28, 2018.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Raj K. Krishnaraju, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6190,
Bethesda, MD 20892, 301–435–1047,
kkrishna@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Integrative Neuroscience.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Date: February 27, 2018.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ying-Yee Kong, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5185,
Bethesda, MD 20892, ying-yee.kong@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Nephrology.
Date: February 27, 2018.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Jonathan K. Ivins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2190,
MSC 7850, Bethesda, MD 20892, (301) 594–
1245, ivinsj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–16–
380: Fundamental Mechanism of Affective
and Decisional Process in Cancer Control.
Date: February 27, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Michael John McQuestion,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
Bethesda, MD 20892, 301–480–1276,
mike.mcquestion@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: January 25, 2018.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–01820 Filed 1–30–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
SUMMARY:
E:\FR\FM\31JAN1.SGM
31JAN1
Federal Register / Vol. 83, No. 21 / Wednesday, January 31, 2018 / Notices
Government and are available for
licensing in the U.S.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by emailing the indicated
licensing contact at the National Heart,
Lung, and Blood, Office of Technology
Transfer and Development Office of
Technology Transfer, 31 Center Drive
Room 4A29, MSC2479, Bethesda, MD
20892–2479; telephone: 301–402–5579.
A signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION: This
notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing. A description of the
technology follows.
sradovich on DSK3GMQ082PROD with NOTICES
Chimeric Antibodies Against Hepatitis
B e-Antigen
Description of Technology: The
invention relates to recombinant
chimeric rabbit/human monoclonal
antibody fragments (Fabs) against
hepatitis B Virus e-antigen (HBeAg),
notably Fab me6. Viral hepatitis is the
seventh leading cause of death
worldwide. Hepatitis B core antigen
(HBcAg) forms an icosahedral structure
containing the viral genome. Both the
HBcAg and the HBeAg of interest here
are expressed by two different start
codons of the viral C gene. Unlike the
related HBcAg which activates type 1 T
helper (Th1) cells leading to immune
attack, the HBeAg activates Th2 cells
which promote immune tolerance. The
long-term persistence of HBeAg is
associated with the development of
hepatocellular carcinoma. Conversely,
HBeAg seroconversion (from HBeAg
carrier to anti-HBeAg carrier) is a
marker for successful therapy of
chronically infected patients. The
presently phage display engineered
antibody Fab me6 shows higher
sensitivity and selectivity against
HBeAg compared to three commercial
diagnostics kits tested; additionally, it
also inhibits capsid assembly which is
essential for viral replication;
furthermore, it can also be fully
humanized and has potential for antihepatitis B virus therapeutic
interventions.
Potential Commercial Applications:
• Hepatitis B therapy.
• Hepatocellular carcinoma
prophylaxis.
VerDate Sep<11>2014
17:36 Jan 30, 2018
Jkt 244001
Development Stage:
• In vitro data available.
Inventors: Paul Winfield, Norman
Watts, Alasdair Steven (all of NIAMS).
Intellectual Property: HHS Reference
No. E–192–2017/0–US–01.
• U.S. Provisional Patent Application
62/534,603 filed July 19, 2017.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@nih.gov.
Collaborative Research Opportunity:
The National Institute of Environmental
Health Sciences seeks statements of
capability or interest from parties
interested in collaborative research to
further develop and evaluate, please
contact Cecilia Pazman, Ph.D.,
Technology Development Specialist,
Office of Technology Transfer, National
Heart, Lung, and Blood Institute, Phone:
(301) 594–4273; pazmance@
nhlbi.nih.gov.
Dated: January 25, 2018.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2018–01928 Filed 1–30–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Skeletal Biology
Development and Disease Study
Section, February 8, 2018, 8:00 a.m. to
February 9, 2018, 3:00 p.m., Westin
Baltimore Washington Airport, 1100
Old Elkridge Landing Road, Linthicum
Heights, MD, 21090 which was
published in the Federal Register on
January 5, 2018, 83 FR PG 683. The
meeting will be held on February 7,
2018 at 3:00 p.m. and end February 8,
2018 at 9:00 p.m. The meeting location
remains the same. The meeting is closed
to the public.
Dated: January 25, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–01821 Filed 1–30–18; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
4499
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the NHLBI Mentored
Transition to Independence Review
Committee.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI
Mentored Transition to Independence
Review Committee.
Date: March 8–9, 2018.
Time: 8:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The William F. Bolger Center, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: Giuseppe Pintucci, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7192, Bethesda, MD 20892, 301–435–0287,
Pintuccig@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: January 26, 2018.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–01930 Filed 1–30–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Advisory
Council on Aging, January 23, 2018,
3:00 p.m. to January 24, 2018, 2:00 p.m.,
National Institutes of Health, Building
E:\FR\FM\31JAN1.SGM
31JAN1
]]>Agencies
[Federal Register Volume 83, Number 21 (Wednesday, January 31, 2018)]
[Notices]
[Pages 4498-4499]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-01928]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
[[Page 4499]]
Government and are available for licensing in the U.S.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the patent applications listed below may be obtained by emailing the
indicated licensing contact at the National Heart, Lung, and Blood,
Office of Technology Transfer and Development Office of Technology
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479;
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may
be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve commercialization of results of
federally-funded research and development. Foreign patent applications
are filed on selected inventions to extend market coverage for
companies and may also be available for licensing. A description of the
technology follows.
Chimeric Antibodies Against Hepatitis B e-Antigen
Description of Technology: The invention relates to recombinant
chimeric rabbit/human monoclonal antibody fragments (Fabs) against
hepatitis B Virus e-antigen (HBeAg), notably Fab me6. Viral hepatitis
is the seventh leading cause of death worldwide. Hepatitis B core
antigen (HBcAg) forms an icosahedral structure containing the viral
genome. Both the HBcAg and the HBeAg of interest here are expressed by
two different start codons of the viral C gene. Unlike the related
HBcAg which activates type 1 T helper (Th1) cells leading to immune
attack, the HBeAg activates Th2 cells which promote immune tolerance.
The long-term persistence of HBeAg is associated with the development
of hepatocellular carcinoma. Conversely, HBeAg seroconversion (from
HBeAg carrier to anti-HBeAg carrier) is a marker for successful therapy
of chronically infected patients. The presently phage display
engineered antibody Fab me6 shows higher sensitivity and selectivity
against HBeAg compared to three commercial diagnostics kits tested;
additionally, it also inhibits capsid assembly which is essential for
viral replication; furthermore, it can also be fully humanized and has
potential for anti-hepatitis B virus therapeutic interventions.
Potential Commercial Applications:
Hepatitis B therapy.
Hepatocellular carcinoma prophylaxis.
Development Stage:
In vitro data available.
Inventors: Paul Winfield, Norman Watts, Alasdair Steven (all of
NIAMS).
Intellectual Property: HHS Reference No. E-192-2017/0-US-01.
U.S. Provisional Patent Application 62/534,603 filed July
19, 2017.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
[email protected].
Collaborative Research Opportunity: The National Institute of
Environmental Health Sciences seeks statements of capability or
interest from parties interested in collaborative research to further
develop and evaluate, please contact Cecilia Pazman, Ph.D., Technology
Development Specialist, Office of Technology Transfer, National Heart,
Lung, and Blood Institute, Phone: (301) 594-4273;
[email protected].
Dated: January 25, 2018.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-01928 Filed 1-30-18; 8:45 am]
BILLING CODE 4140-01-P
